Chonluten Dosage: Immune Research Protocol

Read this first

Dosage and protocol figures on this page are reproduced only from the matching PeptideDosages.com protocol. The 3 ml table is arithmetic based on those source amounts and the listed vial sizes. Educational research only — not instructions or medical advice.

Dosage chart

The dosage amounts and schedules below come only from PeptideDosages.com. Syringe-unit figures are mathematical conversions of those source amounts using exactly 3 ml of bacteriostatic water. Educational reference only — not instructions or medical advice.

Chonluten · 20 mg Vial

Chonluten is dosed at 250 mcg–4 mg daily via subcutaneous injection in educational protocols.

Typical daily range: 250–4,000 mcg once daily (gradual titration over 8–16 weeks).

Standard / Gradual Approach

Week	Daily Dose (mcg)
Weeks 1–2	250 mcg (0.25 mg)
Weeks 3–4	500 mcg (0.5 mg)
Weeks 5–6	1,000 mcg (1 mg)
Weeks 7–8	1,500 mcg (1.5 mg)
Weeks 9–10	2,000 mcg (2 mg)
Weeks 11–12	3,000 mcg (3 mg)
Weeks 13–14	4,000 mcg (4 mg)
Weeks 15–16	4,000 mcg (4 mg)

3 ml conversion

Select vial strength

20 mg + 3 ml = 6.67 mg/ml. Choose your vial strength to update the units below.

Source dose	U-100 syringe
250 mcg	3.7 units
500 mcg	7.5 units
0 mcg	0.0 units
1 mg	15 units
1.5 mg	23 units
2 mg	30 units
3 mg	45 units
4 mg	60 units

Source chart on peptidedosages.com

Other immune compounds

KPVα-MSH C-terminal tripeptide LL-3737-amino-acid cathelicidin antimicrobial peptide ThymalinThymic peptide extract preparation Thymosin Alpha-128-amino-acid thymic peptide VilonSynthetic immunoregulatory dipeptide VIP28-amino-acid neuropeptide

All research protocols

Chonluten: research background

What the compound is

Chonluten is a tripeptide (Glu-Asp-Gly) derived from bronchial epithelial cells (PMID 35408963).

How it is thought to work

Chonluten can modulate key proliferative patterns by increasing tyrosine phosphorylation of mitogen-activated cytoplasmic kinases in cells (PMID 35408963). It has been shown to inhibit tumor necrosis factor (TNF) production in monocytes exposed to pro-inflammatory bacterial lipopolysaccharide (LPS) (PMID 35408963). This reduction in TNF release is linked to a mechanism called TNF tolerance, which promotes the attenuation of inflammatory action (PMID 35408963). Chonluten also inhibited the expression of TNF and the pro-inflammatory cytokine IL-6 stimulated by LPS in differentiated THP-1 cells (PMID 35408963). Additionally, it reduced cell adhesion in a co-culture model of activated endothelial cells and peptide-treated THP-1 cells, suggesting an anti-inflammatory mechanism (PMID 35408963).

What laboratory studies report

In human monocytic THP-1 cells, Chonluten modulated proliferative activity and inflammatory pathways (PMID 35408963). Specifically, it inhibited TNF production of monocytes exposed to pro-inflammatory bacterial LPS (PMID 35408963). It also inhibited the expression of TNF and pro-inflammatory IL-6 cytokine stimulated by LPS on terminally differentiated THP-1 cells (PMID 35408963). When THP-1 cells treated with Chonluten were placed on a layer of activated endothelial cells, a reduction in cell adhesion was observed (PMID 35408963). These findings suggest Chonluten acts as an anti-inflammatory molecule in monocytes and macrophages during inflammatory and microbial-mediated activity (PMID 35408963).

Open questions and limitations

The provided abstracts describe Chonluten's effects in an in vitro cell line model (THP-1 cells) (PMID 35408963). Further research in animal models and human studies would be necessary to understand its full biological and therapeutic potential beyond these initial cellular observations.

Studies cited in this section

Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. — International journal of molecular sciences, 2022 (PMID 35408963)

Summarised from the PubMed abstracts listed above. Educational reference only — not medical advice or instructions.

Nearby in the protocol A–Z

Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.

Chonluten dosage protocol